dapagliflozin

Dapagliflozin (BMS-512148) is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity.

Dapagliflozin impurity is the enantiomer of Dapagliflozin, Dapagliflozin is a sodium glucose transporter 2 inhibitor.

Dapagliflozin-D5 is a deuterated form of Dapagliflozin (T2389), a competitive SGLT2 inhibitor.

Dapagliflozin impurity A (Compound A) is a peroxidized form of dapagliflozin known to be a genotoxic impurity. Even at low concentrations, it can damage human genetic material, potentially causing gene mutations and potentially promoting tumor development.

Dapagliflozin methyl acetate is an orally active inhibitor of sodium/glucose co-transporter protein 2 (SGLT2). It is utilized in research related to type 2 diabetes.

O-Desethyl Dapagliflozin (Empagliflozin-4) is a SGLT2 inhibitor, IC50=33nM.

Dapagliflozin impurity 112 is a contaminant associated with Dapagliflozin.

Dapagliflozin impurity 111 is an impurity of Dapagliflozin.

Dapagliflozin impurity 2 is classified as an impurity of Dapagliflozin.

Dapagliflozin ((2S)-1,2-propanediol, hydrate) (BMS-512148 (2S)-1,2-propanediol, hydrate) is a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2), in development for treating type 2 diabetes mellitus (T2DM). It inhibits SGLT2, responsible for at least 90% of glucose reabsorption in the kidney.

Dapagliflozin-3-O-β-D-glucuronide is a metabolite of dapagliflozin . Dapagliflozin is a first generation selective sodium glucose cotransporter (SGLT) 2 inhibitor that blocks glucose transport.[1] Dapagliflozin is metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A9 to dapagliflozin-3-O-β-D-glucuronide, which is 2,600-fold less potent than the parent compound with regard to SGLT2 inhibition.[2]

Dapagliflozin-13C6 (glucitol-13C6) is the 13C labeled compound of Dapagliflozin. Dapagliflozin (T2389) has a CAS number of 461432-26-8. Dapagliflozin (T2389) is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity.

Dapagliflozin (Standard) is a reference standard for research and analysis in studies involving Dapagliflozin. Dapagliflozin (BMS-512148) is a glucose co-transporter protein 2 (SGLT2) inhibitor that competitively binds to its target. Dapagliflozin is used in the treatment of type 2 diabetes mellitus and decreases glucose reabsorption in the kidneys and increases urinary excretion of glucose, which results in lowering plasma glucose levels.

Dapagliflozin-[13C6] (Standard) is a reference standard of Dapagliflozin-[13C6] intended for quantitative analysis, quality control, and related biochemical research applications.

3-Bromo-4-chlorobenzoic acid (Dapagliflozin Impurity 50) functions as a pharmaceutical intermediate in the synthesis of various active compounds.